{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:19:53Z","timestamp":1761823193777,"version":"3.44.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["P41 RR010888","S10 RR020946","R33 DK070326","P01 NS045242"],"award-info":[{"award-number":["P41 RR010888","S10 RR020946","R33 DK070326","P01 NS045242"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Analytical Biochemistry"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1016\/j.ab.2010.01.010","type":"journal-article","created":{"date-parts":[[2010,1,15]],"date-time":"2010-01-15T00:54:54Z","timestamp":1263516894000},"page":"152-161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Identification of phenylbutyrate-generated metabolites in Huntington disease patients using parallel liquid chromatography\/electrochemical array\/mass spectrometry and off-line tandem mass spectrometry"],"prefix":"10.1016","volume":"399","author":[{"given":"Erika N.","family":"Ebbel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nancy","family":"Leymarie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Schiavo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swati","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sona","family":"Gevorkian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Hersch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne R.","family":"Matson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine E.","family":"Costello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ab.2010.01.010_bib1","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1126\/science.1072613","article-title":"Sp1 and TAFII130 transcriptional activity disrupted in early Huntington\u2019s disease","volume":"296","author":"Dunah","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.ab.2010.01.010_bib2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0968-0004(03)00168-3","article-title":"The hunt for huntingtin function: Interaction partners tell many different stories","volume":"28","author":"Harjes","year":"2003","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.ab.2010.01.010_bib3","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0168-9525(03)00074-X","article-title":"Transcriptional abnormalities in Huntington disease","volume":"19","author":"Sugars","year":"2003","journal-title":"Trends Genet."},{"key":"10.1016\/j.ab.2010.01.010_bib4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1042\/BJ20071619","article-title":"Huntington\u2019s disease: From pathology and genetics to potential therapies","volume":"412","author":"Imarisio","year":"2008","journal-title":"Biochem. J."},{"key":"10.1016\/j.ab.2010.01.010_bib5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00005072-199805000-00001","article-title":"Huntington disease","volume":"57","author":"Vonsattel","year":"1998","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ab.2010.01.010_bib6","doi-asserted-by":"crossref","first-page":"15179","DOI":"10.1073\/pnas.261400698","article-title":"Histone deacetylase inhibitors reduce polyglutamine toxicity","volume":"98","author":"McCampbell","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ab.2010.01.010_bib7","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/35099568","article-title":"Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila","volume":"413","author":"Steffan","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.ab.2010.01.010_bib8","doi-asserted-by":"crossref","first-page":"13201","DOI":"10.1073\/pnas.191498198","article-title":"Altered transcription in yeast expressing expanded polyglutamine","volume":"98","author":"Hughes","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ab.2010.01.010_bib9","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1073\/pnas.0437870100","article-title":"Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington\u2019s disease","volume":"100","author":"Hockly","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ab.2010.01.010_bib10","doi-asserted-by":"crossref","first-page":"9418","DOI":"10.1523\/JNEUROSCI.23-28-09418.2003","article-title":"Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington\u2019s disease mice","volume":"23","author":"Ferrante","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ab.2010.01.010_bib11","doi-asserted-by":"crossref","first-page":"15564","DOI":"10.1073\/pnas.0804249105","article-title":"The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington\u2019s disease transgenic mice","volume":"105","author":"Thomas","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ab.2010.01.010_bib12","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/978-1-4615-5325-0_67","article-title":"Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers","volume":"400","author":"Samid","year":"1997","journal-title":"Adv. Exp. Med. Biol. A"},{"key":"10.1016\/j.ab.2010.01.010_bib13","first-page":"2292","article-title":"A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies","volume":"7","author":"Gilbert","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ab.2010.01.010_bib14","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1038\/sj.onc.1206502","article-title":"Inhibition of histone deacetylase activity increases chromosomal instability by the aberrant regulation of mitotic checkpoint activation","volume":"22","author":"Shin","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.ab.2010.01.010_bib15","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/blood.V84.1.339.339","article-title":"Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate","volume":"84","author":"Dover","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.ab.2010.01.010_bib16","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1164\/ajrccm.157.2.9706088","article-title":"A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in delta F508-homozygous cystic fibrosis patients: Partial restoration of nasal epithelial CFTR function","volume":"157","author":"Rubenstein","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ab.2010.01.010_bib17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/156720506778249407","article-title":"Histone deacetylase inhibitors: A novel therapeutic approach to Huntington\u2019s disease (complex mechanism of neuronal death)","volume":"3","author":"Sadri-Vakili","year":"2006","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.ab.2010.01.010_bib18","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1124\/dmd.32.1.10","article-title":"New secondary metabolites of phenylbutyrate in humans and rats","volume":"32","author":"Kasumov","year":"2004","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ab.2010.01.010_bib19","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/jms.316","article-title":"Identification of phenylbutyrylglutamine, a new metabolite of phenylbutyrate metabolism in humans","volume":"37","author":"Comte","year":"2002","journal-title":"J. Mass Spectrom."},{"key":"10.1016\/j.ab.2010.01.010_bib20","first-page":"1","article-title":"Phase 2 study of sodium phenylbutyrate in ALS","author":"Cudkowicz","year":"2008","journal-title":"Amyotroph Lateral Scler."},{"key":"10.1016\/j.ab.2010.01.010_bib21","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1021\/ac800507y","article-title":"Metabolite identification using a nanoelectrospray LC\u2013EC-array\u2013MS integrated system","volume":"80","author":"Schiavo","year":"2008","journal-title":"Anal. Chem."},{"key":"10.1016\/j.ab.2010.01.010_bib22","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/brain\/awm304","article-title":"Metabolomic profiling to develop blood biomarkers for Parkinson\u2019s disease","volume":"131","author":"Bogdanov","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.ab.2010.01.010_bib23","first-page":"99","article-title":"The measurement of markers of oxidative damage, antioxidants, and related compounds using HPLC and coulometric array analysis","volume":"6","author":"Gamache","year":"1997","journal-title":"Prog. HPLC\u2013HPCE"},{"key":"10.1016\/j.ab.2010.01.010_bib24","first-page":"127","article-title":"CEAS generation of large multiparameter metabolic databases for determining categorical process involvement of biological molecules","volume":"6","author":"Milbury","year":"1997","journal-title":"Prog. HPLC\u2013HPCE"},{"key":"10.1016\/j.ab.2010.01.010_bib25","first-page":"185","article-title":"Simultaneous analysis of multiple redox-active metabolites from biological matrices","volume":"186","author":"Kristal","year":"2002","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ab.2010.01.010_bib26","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1006\/abio.1998.2831","article-title":"Simultaneous analysis of the majority of low-molecular-weight, redox-active compounds from mitochondria","volume":"263","author":"Kristal","year":"1998","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ab.2010.01.010_bib27","doi-asserted-by":"crossref","first-page":"5635","DOI":"10.1021\/ac010501i","article-title":"Reduction of signal suppression effects in ESI\u2013MS using a nanosplitting device","volume":"73","author":"Gangl","year":"2001","journal-title":"Anal. Chem."},{"unstructured":"National Institutes of Health, Safety and tolerability study of phenylbutyrate in Huntington\u2019s disease (PHEND\u2013HD), 2005, http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00212316?term=00212316&rank=1.","key":"10.1016\/j.ab.2010.01.010_bib28"},{"key":"10.1016\/j.ab.2010.01.010_bib29","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/01.wnl.0000194318.74946.b6","article-title":"Creatine in Huntington disease is safe, tolerable, bioavailable in brain, and reduces serum 8OH2\u2019dG","volume":"66","author":"Hersch","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.ab.2010.01.010_bib30","first-page":"453","article-title":"Neurotoxic properties of a serotonin oxidation product: Possible role in Alzheimer\u2019s disease","volume":"317","author":"Volicer","year":"1989","journal-title":"Prog. Clin. Biol. Res."},{"key":"10.1016\/j.ab.2010.01.010_bib31","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0006-8993(89)91364-4","article-title":"Neurotoxic effects of partially oxidized serotonin: Tryptamine-4,5-dione","volume":"504","author":"Crino","year":"1989","journal-title":"Brain Res."},{"key":"10.1016\/j.ab.2010.01.010_bib32","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1001\/archneur.1985.04060110040013","article-title":"Serotoninergic system in dementia of the Alzheimer type: Abnormal forms of 5-hydroxytryptophan and serotonin in cerebrospinal fluid","volume":"42","author":"Volicer","year":"1985","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.ab.2010.01.010_bib33","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1111\/j.1471-4159.1990.tb03143.x","article-title":"Kynurenine pathway measurements in Huntington\u2019s disease striatum: Evidence for reduced formation of kynurenic acid","volume":"55","author":"Beal","year":"1990","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ab.2010.01.010_bib34","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/0022-510X(92)90191-M","article-title":"Kynurenic acid concentrations are reduced in Huntington\u2019s disease cerebral cortex","volume":"108","author":"Beal","year":"1992","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.ab.2010.01.010_bib35","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1471-4159.1982.tb10864.x","article-title":"On the nature of the interaction between serotonin and serotonin binding protein: Effect of nucleotides, ions, and sulfhydryl reagents","volume":"38","author":"Tamir","year":"1982","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ab.2010.01.010_bib36","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1021\/bi051737+","article-title":"3-Hydroxykynurenine oxidizes \u03b1-crystallin: Potential role in cataractogenesis","volume":"45","author":"Korlimbinis","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.ab.2010.01.010_bib37","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1021\/bi051744y","article-title":"Identification of 3-hydroxykynurenine bound to proteins in the human lens: A possible role in age-related nuclear cataract","volume":"45","author":"Korlimbinis","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.ab.2010.01.010_bib38","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.freeradbiomed.2004.07.015","article-title":"Protein-bound kynurenine is a photosensitizer of oxidative damage","volume":"37","author":"Parker","year":"2004","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ab.2010.01.010_bib39","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1111\/j.1471-4159.1991.tb03440.x","article-title":"Modification of brain guanine nucleotide-binding regulatory proteins by tryptamine-4,5-dione, a neurotoxic derivative of serotonin","volume":"56","author":"Fishman","year":"1991","journal-title":"J. Neurochem."},{"year":"2005","series-title":"Bioimaging in Neurodegeneration","key":"10.1016\/j.ab.2010.01.010_bib40"},{"key":"10.1016\/j.ab.2010.01.010_bib41","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1471-4159.2008.05350.x","article-title":"Increased levels of \u03b3-glutamylamines in Huntington disease CSF","volume":"106","author":"Jeitner","year":"2008","journal-title":"J. Neurochem."}],"container-title":["Analytical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003269710000254?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003269710000254?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T20:57:28Z","timestamp":1757710648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003269710000254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["S0003269710000254"],"URL":"https:\/\/doi.org\/10.1016\/j.ab.2010.01.010","relation":{},"ISSN":["0003-2697"],"issn-type":[{"type":"print","value":"0003-2697"}],"subject":[],"published":{"date-parts":[[2010,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of phenylbutyrate-generated metabolites in Huntington disease patients using parallel liquid chromatography\/electrochemical array\/mass spectrometry and off-line tandem mass spectrometry","name":"articletitle","label":"Article Title"},{"value":"Analytical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ab.2010.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}